Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2020 | Potential of ADAR pathway in immunotherapy

Jeffrey Ishizuka • 28 Sep 2020
ITOC 2020

Jeffrey Ishizuka, MD, DPhil, Yale School of Medicine, New Haven, CT, highlights the potential of the ADAR1 pathway in immunotherapy. Dr Ishizuka mentions different mechanisms of resistance to immunotherapy and explains how using functional genomics (such as CRISPR/Cas9) has enabled for the identification of ADAR1. Many patients do not respond to immunotherapy due to MHC-I down-regulation, but deleting ADAR1 restores response to immunotherapy. Dr Ishizuka provides an in-depth explanation of the mechanism of action of the ADAR1 pathway and its potential role in immunotherapy. This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.

More from Jeffrey Ishizuka

Translation into therapeutic strategies: the ADAR pathway
1:34
Translation into therapeutic strategies: the ADAR pathway
Jeffrey Ishizuka • 28 Sep 2020
ADAR inhibition: patient stratification
1:21
ADAR inhibition: patient stratification
Jeffrey Ishizuka • 3 Nov 2020

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals